Alexis Borisy is the first person to admit he has a lot of projects going on. “I’m a man of many hats,” he said during a Zoom call, gesturing to one of his trademark fedoras. “My hobby is creating companies. That’s what I love to do. It soothes me.”
He left biotech venture capital firm Third Rock Ventures in 2019 to start a company dedicated to making drugs less expensive. Earlier this year, he announced he’s starting an incubator and investment firm for biotech founders named Curie Bio.
On Tuesday, he launched another project, a company called IDRx that plans to combine multiple drug compounds to create precise, durable cancer treatments. It’s the first company to come out of yet another Borisy project, an incubator dubbed Borisy Labs. The pitch brought in a $122 million Series A round from Andreessen Horowitz, Casdin Capital, and other investors.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect